<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745589</url>
  </required_header>
  <id_info>
    <org_study_id>A111-104</org_study_id>
    <nct_id>NCT00745589</nct_id>
  </id_info>
  <brief_title>Sevelamer Hydrochloride in Peritoneal Dialysis Patients</brief_title>
  <official_title>Use of Sevelamer Hydrochloride to Control Hyperphosphatemia and Reduce Calcification Burden in the Poor Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the hypothesis that second-line fixed low-dose sevelamer hydrochloride therapy is as
      effective as first-line high-dose sevelamer hydrochloride therapy in limiting the progression
      of cardiovascular calcification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease accounts for nearly 50% of the mortality and is the most frequent
      cause of hospitalization in ESRD patients. Hyperphosphatemia is increasingly recognized to be
      an important predictor of mortality and cardiovascular death in ESRD patients and is largely
      attributed to the increased prevalence of vascular calcification.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in coronary artery and cardiac valvular calcification</measure>
    <time_frame>12 months, 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in aortic pulse wave velocity, bone mineral density of distal radius, femur and lumbar spine. Incidence of cardiovascular and non-cardiovascular related hospitalizations</measure>
    <time_frame>12 months, 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Endstage Renal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first-line high dose sevelamer hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>second-line fixed low-dose sevelamer hydrochloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevelamer hydrochloride</intervention_name>
    <description>First-line high dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Renagel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ESRD patients receiving long-term peritoneal dialysis treatment with hyperphosphatemia
             currently receiving aluminum-based phosphorus binders or whose phosphorus control
             remains suboptimal with calcium-based binders only

          -  Patients who cannot afford to self-pay sevelamer hydrochloride.

          -  Patients who provided informed consent for the study

        Exclusion Criteria:

          -  Patients with underlying active malignancy

          -  Patients with cyanotic congenital heart disease

          -  Patients with poor general condition

          -  Patients with plan for living related kidney transplant within coming 1 year

          -  Female patients with pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela YM Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital, Tung Wah Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>0000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>January 7, 2017</last_update_submitted>
  <last_update_submitted_qc>January 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Angela Yee-Moon Wang</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>vascular,</keyword>
  <keyword>valvular calcification,</keyword>
  <keyword>phosphate binder,</keyword>
  <keyword>sevelamer,</keyword>
  <keyword>endstage renal disease</keyword>
  <keyword>peritoneal dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

